Boston Children’s leverages IBM Watson to take on pediatric diseases

A new collaboration between Boston Children’s Hospital and IBM Watson will allow clinicians to use Watson’s cognitive platform for clinical decision support in the diagnosis and treatment of rare pediatric diseases.

Advertisement

Initially, the partnership will focus on kidney disease. Watson will analyze large volumes of scientific literature and clinical databases on the Watson Health Cloud to uncover insights to help clinicians identify treatment options.

Clinicians at Boston Children’s will help further train Watson in nephrology by inputting related literature into the supercomputer, as well as genomic sequencing data from patients. Ultimately, the goal is to develop a cognitive system that helps clinicians interpret a genome sequencing data and use existing literature to identify diagnoses and treatments.

“Coping with an undiagnosed illness is a tremendous challenge for many of the children and families we see,” said Christopher Walsh, MD, PhD, director of the Division of Genetics and Genomics at Boston Children’s. “Watson can help us ensure we’ve left no stone unturned in our search to diagnose and cure these rare diseases so we can uncover all relevant insights from the patient’s clinical history, DNA data, supporting evidence and population health.”

More articles on IBM Watson:

Can IBM take over Amazon, Microsoft & Google in cloud computing?
IBM Watson comes to Apple Watch: 5 things to know
Perspective: Is IBM Watson all it’s cracked up to be?

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Health IT

Advertisement

Comments are closed.